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effective than monotherapy, as shown by enhanced effects 
on immune cell infiltration; activation; increased cytokine 
secretion; and faster, more efficient elimination of targeted 
cells. This study demonstrates that the 3D heterotypic sphe-
roid model provides a novel and versatile tool for in vitro 
evaluation of cancer immunotherapy agents and allows for 
assessment of additional aspects of the activity of cancer 
immunotherapy agents, including analysis of immune cell 
infiltration and drug targeting.
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CBA  Cytometric bead array
CEA  Carcinoembryonic antigen
CEA TCB  Carcinoembryonic antigen-targeted T cell 
bispecific antibody
DPBS  Dulbecco’s phosphate-buffered saline
ECM  Extracellular matrix
EMEM  Eagle’s minimum essential medium
FAP  Fibroblast activation protein-α
FGM-2  Fibroblast growth medium-2
TCB  T cell bispecific antibody
Tregs  Regulatory T cells
Introduction
Traditionally, anticancer treatments have been tested in 
classical two-dimensional (2D) culture systems, but these 
Abstract The complexity of the tumor microenvironment is 
difficult to mimic in vitro, particularly regarding tumor–host 
interactions. To enable better assessment of cancer immuno-
therapy agents in vitro, we developed a three-dimensional 
(3D) heterotypic spheroid model composed of tumor cells, 
fibroblasts, and immune cells. Drug targeting, efficient stim-
ulation of immune cell infiltration, and specific elimination 
of tumor or fibroblast spheroid areas were demonstrated fol-
lowing treatment with a novel immunocytokine (interleu-
kin-2 variant; IgG-IL2v) and tumor- or fibroblast-targeted 
T cell bispecific antibody (TCB). Following treatment with 
IgG-IL2v, activation of T cells, NK cells, and NKT cells 
was demonstrated by increased expression of the activa-
tion marker CD69 and enhanced cytokine secretion. The 
combination of TCBs with IgG-IL2v molecules was more 
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models suboptimally reproduce the complex morphologi-
cal and histopathological features characteristic of tumor 
microenvironments, particularly concerning tumor–host 
and tumor–immune cell interactions, which limits their 
value as models for cancer immunotherapy drug develop-
ment [1]. Currently, there is limited availability of in vitro 
models that adequately mimic in vivo conditions. Com-
pared to 2D cultures, three-dimensional (3D) models better 
predict in vivo immune cell behavior [2], thereby provid-
ing a more robust system to evaluate immunotherapeutic 
agents.
Cells cultured in 3D culture systems (spheroids) are phe-
notypically different to those grown in 2D culture systems 
(monolayers), as shown by differential gene expression 
[3–10]. In particular, expression of genes encoding signal 
transduction proteins, and cell surface markers, and locali-
zation and oligomerization of these markers in 3D cancer 
spheroids were shown to be more similar to the in vivo 
environment [11, 12]. The 3D microenvironment, includ-
ing the extracellular matrix (ECM), is profoundly altered 
in tumors [13, 14], and 3D spheroid models simulate these 
alterations [15]. In 3D spheroids, the development of extra-
cellular matrix (ECM), the distribution of oxygen and 
metabolites, and cell proliferation gradients are more simi-
lar to those of cancer tissues than those of 2D culture mod-
els and more closely resemble avascular or intervascular 
tumor microregions [10, 16–20]. Therefore, 3D spheroid 
systems constitute a more physiological model for in vitro 
testing of drugs [12, 21–23]. In addition to structural fea-
tures, 3D cultures offer temporal advantages because they 
also allow kinetic analysis of therapeutic activity, which is 
suboptimally assessed in 2D cultures owing to fast and effi-
cient immune cell activation and target cell lysis (unpub-
lished data).
The behavior of the immune cells is also affected by the 
infiltration dynamics within a 3D scaffold due to physical 
constraints and chemical cues. Infiltration of immune cells 
was studied in benign and malignant cell spheroids, where 
it was found that stimulation of human peripheral blood 
mononuclear cells (PBMCs) by tumor cells or IL-2 was 
necessary for the infiltration of PBMCs into the spheroids 
[24]. In 3D melanoma spheroids, tumor cells had a higher 
capacity to inhibit both T cell activation and proliferation 
than in 2D cultures, suggesting that spheroids support a 
more physiological immune-modulatory function than 2D 
cultures [25]. Cell-killing assays in 3D models have shown 
comparable results to in vivo experiments [26]. Tumor 3D 
homotypic spheroids were also shown to be a more appro-
priate model than classical 2D cultures for studying the 
cytotoxicity and infiltration of NK cells, allowing stable, 
reproducible, and long-term co-culture with immune cells 
and enabling the characterization of immune cell subpopu-
lations [27].
We explored the versatility of a newly developed 3D 
heterotypic spheroid model composed of tumor cells, 
fibroblasts, and immune cells by studying drug target-
ing and immune cell infiltration, activation, and cytotox-
icity in response to novel cancer immunotherapy agents 
currently in Phase I clinical trials (IgG-IL2v and T cell 
bispecific antibodies [TCBs]) as monotherapy and in 
combination.
IgG-IL2v is a monomeric IL2 variant fused to an IgG1 
antibody with FcγR-silent Fc that is either targeted to car-
cinoembryonic antigen (CEA)–expressing tumors (CEA-
IL2v), fibroblast activation protein-α-expressing fibroblasts 
(FAP-IL2v), or untargeted (DP47-IL2v = IgG-IL2v). The 
IL2v mutations abolish binding to the alpha subunit of 
the IL2 receptor (IL2Rα, CD25) and result in an IL2 vari-
ant (IL2v) that lacks the preferential activation of regu-
latory T cells (Tregs) by normal IL-2, binding only to the 
IL2 receptor βγ complex and thus leads to activation and 
expansion of CD8+ effector, CD4+ helper T cells and NK 
cells in vitro and in vivo [28, 29]. Phase I clinical trials 
with CEA-IL2v as well as FAP-IL2v are currently ongoing 
(NCT02350673 and NCT02627274) [30, 31].
CEA-targeted TCB (CEA TCB) is a novel tumor-tar-
geted T cell bispecific antibody that binds simultaneously 
to CEA overexpressed on many solid tumors (colorectal, 
pancreatic, gastric, lung, breast, and ovarian carcinomas) 
and to CD3 (epsilon chain, CD3e) present on T cells. In the 
presence of CEA-expressing target cells and T cells, treat-
ment with CEA TCB leads to rapid formation of immuno-
logical synapses and T cell activation followed by T cell-
mediated killing of tumor cells, T cell proliferation and 
cytokine release [32–34]. Phase I clinical trials with CEA 
TCB are currently ongoing (NCT02324257) [35]. FAP 
TCB is a fibroblast-targeted TCB that binds to FAP and the 
CD3e antigen.
Materials and methods
Cell lines and 3D heterotypic spheroid cultures
Human colon adenocarcinoma cells LS174T (ECACC 
87060401) and LoVo (ECACC 87060101) were cultured in 
Eagle’s Minimum Essential Media (EMEM; Gibco®, Life 
Technologies, Zug, Switzerland) and DMEM (Gibco®, Life 
Technologies, Zug, Switzerland), respectively; MRC-5 nor-
mal fetal lung fibroblast cells (ATCC CCL-171) and CCD-
18Co a normal colon fibroblast cell line (ATCC CRL-1459) 
were cultured in EMEM or fibroblast growth medium-2 
(FGM™-2; Lonza, Basel, Switzerland). Media were sup-
plemented with 10% FBS (Gibco®, Life Technologies, Zug, 
Switzerland), 2 mM GlutaMax (Gibco®, Life Technologies, 
Zug, Switzerland), 1% nonessential amino acid solution 
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(NEAA, 100×, Sigma-Aldrich Chemie GmbH, Buchs, 
Switzerland), and 1 mM sodium pyruvate (Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland). Cells were cultured 
in a humidified atmosphere of 5% CO2 at 37 °C and split 
every 2–3 days at a ratio of 1:5 (LS174T and LoVo) and 1:2 
(MRC-5, CCD-18Co).
3D heterotypic spheroid cultures were generated 
by hanging drop method using the GravityPLUS™ kit 
(InSphero AG, Schlieren, Switzerland) at a ratio of 1:50 
(tumor cells to fibroblasts). Spheroids were cultured in 
FGM™-2 supplemented with 10% FBS. Cultures were 
incubated in a humidified atmosphere of 5% CO2 at 37 °C 
for 3 days. Spheroid compaction was confirmed by obser-
vation under a microscope, before transferring spheroids 
to GravityTRAP™ assay plates (InSphero AG, Schlieren, 
Switzerland).
PBMCs were isolated from healthy donors by standard 
Histopaque density gradient centrifugation and added to 
the supernatant.
For IL2 (Proleukin [aldesleukin], Novartis) and IgG-
IL2v antibody monotherapy assays, heterotypic sphe-
roids were incubated with PBMCs and IgG-IL2v antibody 
(100 nM) for 24 h. For TCB monotherapy assays, hetero-
typic spheroids were incubated for 24, 48, and 72 h with 
PBMCs (PBMCs to fibroblasts 10:1) and TCBs (50 nM). 
For IgG-IL2v and TCBs combination therapy assays, het-
erotypic spheroids were pre-incubated for 16 h with untar-
geted (DP47) IgG-IL2v (10 nM) and PBMCs (PBMCs to 
fibroblasts 10:1). On the following day, the heterotypic 
spheroids and PBMCs were washed with fresh media and 
then cultured for 24, 48, and 72 h in medium containing 
TCBs (50 nM). Non-treatment control assays were per-
formed in the presence and absence of PBMCs.
Targeting of IgG‑IL2v in the heterotypic spheroid 
model
Fluorescently labeled CEA-targeted, FAP-targeted, and 
untargeted IgG-IL2v cytokines were used to monitor tar-
geting in 3D heterotypic spheroids. 3D heterotypic sphe-
roids were incubated for 16 h in media containing 100 nM 
labeled IgG-IL2v. Media were replaced to remove unbound 
IgG-IL2v before rinsing the cells in Dulbecco’s phos-
phate-buffered saline (DPBS) and fixing in 4% paraform-
aldehyde for 1 h at room temperature. Cells were embed-
ded in mounting medium containing DAPI (InSphero AG, 
Schlieren, Switzerland) and transferred onto glass slides 
prior to 2-photon confocal microscopy. Two-photon con-
focal microscopy provided high-resolution imaging of the 
inner spheroid core and detection of the bound fluores-
cently labeled IgG-IL2v. Tumor and fibroblast compart-
ments were identified based on morphology.
Immunohistochemistry and quantification
For IHC analysis, heterotypic spheroids were embedded 
in paraffin wax. Staining was performed on 3-µm thick 
serial sections of the heterotypic spheroids mounted onto 
poly-L-lysine-coated glass slides. The morphology of the 
sectioned heterotypic spheroids was evaluated after H&E 
staining. IHC was performed by SophistoLab® (Muttenz, 
Switzerland) using the horseradish peroxidase Bond Poly-
mer Refine Detection kit (Leica Biosystems AG, Muttenz, 
Switzerland) and analyzed using the BOND-MAX instru-
ment (Leica Microsystems Newcastle Ltd, Newcastle, 
UK) as per manufacturer’s guidelines. Primary antibodies 
used for staining were: anti-human CD3 (clone SP7, Neo-
Markers Inc., Fremont, US); anti-human CEA (produced 
in-house), anti-human CD45 (clone 2B11 & PD7/26; Cell 
Marque Lifescreen Ltd, Rocklin, US), anti-human CD14 
(ab45870, Abcam Ltd, Cambridge, UK), and antihuman 
Seprase monoclonal antibody (Clone D8) (Vitatex Inc., 
Stony Brook, US).
CEA+ (tumor cells), CEA− (fibroblasts), and CD3+ 
(infiltrated T cells) areas were quantified by digital immu-
nostained slides using ImageJ software (National Institutes 
of Health). CEA+ and CEA− areas were quantified by 
normalization to the total heterotypic spheroid area. The 
CD3+ areas within tumor and fibroblast compartments 
were quantified by normalization to the total tumor and 
fibroblast-rich areas, respectively. Tumor and fibroblast 
compartments were identified by morphology. Statistical 
analysis was performed by Student’s t test.
Cytokine/chemokine release by cytometric bead array
Cytokine/chemokine secretion in the supernatant was 
measured by flow cytometry, using the Cytometric Bead 
Array (CBA, BD Biosciences, Franklin Lakes, NJ, USA), 
according to the manufacturer’s guidelines. Superna-
tants from individual heterotypic spheroids were collected 
and stored at −20 °C. Supernatants were subsequently 
thawed, and 1 well (50 µL) and 5 pooled wells (150 µL) 
were analyzed under each treatment condition for IgG-
IL2v monotherapy and TCB monotherapy/combination 
therapy experiments, respectively. The following CBA kits 
(BD Biosciences, Franklin Lakes, NJ, USA) were used: 
CBA human IFNγ Flex Set, CBA human Granzyme B Flex 
Set, CBA human RANTES Flex Set (D4), CBA human 
MIP-1β Flex Set (E4), CBA human TNF Flex Set, CBA 
human IL-1β Flex Set (B4), and CBA human IL-6 Flex 
Set. Samples were measured using the BD FACS Canto II, 
and analyses were performed using the Diva Software (BD 
Biosciences, Franklin Lakes, NJ, USA). Assays were per-
formed in triplicate.
132 Cancer Immunol Immunother (2017) 66:129–140
1 3
Flow cytometry
Tumor/fibroblast (ratio 1:50) heterotypic spheroids were 
incubated with 5 × 104 PBMCs per well. Following treat-
ment, the external tumor layer of the heterotypic spheroids 
was dissociated by 5 min incubation at room temperature 
in enzyme-free, phosphate-buffered saline-based cell dis-
sociation buffer (Gibco®, Life Technologies, Zug, Switzer-
land). The remaining central core of fibroblasts with resid-
ual tumor cells was dissociated by 10–20 min incubation 
with 0.64 mg/mL Dispase II and 1 mg/mL Collagenase D 
(Roche Diagnostics, Mannheim, Germany). The single-cell 
suspension was washed with DPBS and resuspended in the 
DPBS containing antibody mixture for cell staining. For 
each condition, 32 heterotypic spheroids were pooled and 
tested in triplicate.
Flow cytometry was performed using anti-CEA labeled 
with Alexa 488 (produced in-house), PerCPCy5.5 anti-
human CD45 (Biolegend, San Diego, CA, USA), Brilliant 
Violet 421 anti-human CD56 (Biolegend, San Diego, CA, 
USA), Brilliant Violet 605 anti-human CD69 (Biolegend, 
San Diego, CA, USA), Brilliant Violet 605 Mouse IgG1, 
κ (kappa) Isotype (Biolegend, San Diego, CA, USA), and 
LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life 
Technologies, Zug, Switzerland). Samples were measured 
using the BD FACS Fortessa. Analyses were performed 
using the Diva Software (BD Biosciences, Franklin Lakes, 
NJ, USA). Assays were performed in triplicate.
Statistics
The statistical analysis was performed using GraphPad 
PRISM software version 6. Error bars represent the stand-
ard deviation in all graphs. Two-tailed, unpaired parametric 
t tests were performed by setting the confidence intervals to 
95% (definition of statistical significance: p < 0.05).
Results
Generation of the heterotypic spheroids
An overview of the generation the heterotypic tumor/fibro-
blast/immune cell spheroids and the histology analysis is 
shown in Fig. 1a, b. During spheroid formation, tumor cells 
(LS174T) and fibroblasts (MRC-5) segregate in two differ-
ent compartments. Tumor cells (identified by CEA+ stain-
ing) form an external peripheral layer, which surrounds the 
central core of fibroblasts (identified by FAP+ staining). 
The central core of fibroblasts secretes a mucopolysaccha-
ridic extracellular matrix, as shown by the Ab-pas stain-
ing (Ab-pas+). The tissue microarchitecture also changes 
over time: Tumor cells, initially forming separate clusters, 
evolve into a continuous external layer that becomes thicker 
over time while the fibroblast compartment becomes more 
compact. This could potentially be due to contractile forces 
















H&E Ab-pas CEA FAP CD3 CD14 CD45
Fig. 1  Heterotypic spheroids generation and histology a Heterotypic 
LS174T/MRC-5 spheroids were generated by co-culturing tumor 
cells (LS174T) and fibroblasts (MRC-5) by hanging drop method at 
a ratio of 1:50. Upon assembly and compaction, spheroids were trans-
ferred to a new assay plate and freshly isolated human PBMCs were 
added to the culture supernatant. b H&E, Ab-pas, and immunohisto-
chemical (CEA, FAP, CD3, CD14, and CD45) staining at 24, 48, and 
72 h on 3-µm thick serial sections of the LS174T/MRC-5 spheroids
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as compared to the high proliferation rate of malignant 
tumor cells. When added to culture supernatants contain-
ing spheroids, the immune cells spontaneously infiltrate the 
heterotypic spheroids, as shown by CD45+ and CD14+ 
staining, which mark leukocytes and monocytes, respec-
tively (Fig. 1b). The spontaneous infiltration of T cells (as 
detected by CD3+ staining) was generally found to be low 
(Fig. 1b).
Similar results were obtained with different cancer cell 
lines and different primary fibroblasts (Supplementary Fig-
ure 1), confirming that the novel heterotypic spheroids con-
taining tumor, fibroblasts, and human immune cells provide 
a suitable and versatile model for the assessment of the 
effects of tumor- and fibroblast-targeted cancer immuno-
therapy agents.
IgG‑IL2v monotherapy‑mediated targeting, infiltration, 
tumor cell lysis, and immune cell activation in the 3D 
heterotypic spheroid model
Targeting of each of the IgG-IL2v molecules (CEA-IL2v, 
FAP-IL2v, and DP47-IL2v) to the various compartments of 
the 3D heterotypic spheroids was assessed using 100 nM 
of fluorescently labeled molecules (Fig. 2) CEA-IL2v 
penetrated the spheroid and remained targeted to the tumor 
cell compartment. FAP-IL2v penetrated the spheroid and 
remained targeted to the fibroblast-rich core, binding to 
fibroblast cells. Untargeted IgG-IL2v penetrated the sphe-
roid but was not retained in any of the spheroid compart-
ments. These results demonstrate the specificity of target-
ing of CEA- and FAP-targeted IgG-IL2v and show that the 
heterotypic spheroid model is suitable for the evaluation of 
tumor- and fibroblast-targeted immunotherapies.
In order to study general effects mediated by untar-
geted IgG-IL2v on immune cell activation and infiltration 
in the heterotypic spheroid model, PBMCs and IgG-IL2v-
antibodies (100 nM) were added simultaneously to culture 
supernatants containing the spheroids. Twenty-four-hour 
treatment with IgG-IL2v enhanced infiltration of immune 
cells, in particular T cells into the heterotypic spheroids, as 
detected by CD45 and CD3 staining, respectively (Fig. 3a–
c). Comparison of untargeted IL-2v to tumor-targeted IL-2v 
and to Proleukin showed that all 3 compounds can induce 
similar amounts of leukocyte infiltration at equal exposure. 
Equal exposure to the different molecules was ensured by 
lack of washing steps after their addition (Supplementary 
Figures 2, 3).
In addition to assessing IgG-IL2v-mediated immune 
cell infiltration into the spheroids, we also evaluated tumor 
cell elimination in the spheroid mediated by IgG-IL2v-
stimulated immune cells using three experimental readouts: 
histological examination, measurement of the reduction 
in spheroid size, and flow cytometry analysis (Fig. 3d–f). 
Compared with a control lacking PBMCs, 3D heterotypic 
spheroids incubated with PBMCs showed some spontane-
ous (therapy-independent) immune cell–mediated killing of 
tumor cells by 24 h, measured by CEA staining of tumor 
cells (Fig. 3d). Elimination of tumor cells was markedly 
enhanced by treatment with untargeted IgG-IL2v, which 
resulted in the complete elimination of the peripheral layer 
of tumor cells surrounding the inner fibroblast core. This 
treatment led to a significant reduction in spheroid size 
(2.1-fold, Fig. 3e) and a reduction in CEA+ cells detected 
by flow cytometry upon dissociation of heterotypic sphe-
roids (by 1.8-fold, Fig. 3f).
In addition to tumor lysis, cytokine/chemokine secre-
tion was also enhanced by the treatment with IgG-IL2v as 
compared with control cultures (Fig. 4a). Twenty-four-hour 
treatment of heterotypic spheroids with untargetd-IL2v led 
to increased cytokine/chemokine secretion, as shown by a 
significant increase in MIP-1ß, Rantes and IFNγ secretion 
and a more modest increase of IL1ß, IL-6, and TNFα. In 
line with the infiltration data, treatment of homo- or het-
erotypic spheroids with equal amounts of Proleukin, untar-
geted IgG-IL2v, or CEA-targeted-IL2v in the supernatants 




















Fig. 2  IgG-IL2v targeting. Heterotypic LoVo/MRC-5 spheroids 
incubated for 16 h with 100 nM of fluorescently labeled tumor-tar-
geted IgG-IL2v (CEA-IL2v, colored red), fibroblast-targeted IgG-
IL2v (FAP-IL2v, colored red), and the corresponding untargeted 
control (untargeted IgG-IL2v, colored red). Based on cell morphol-
ogy, CEA-IL2v localized to the tumor cell compartment, FAP-IL2v 
localized to the fibroblast compartment, and the untargeted IgG-IL2v 
was not retained in any of the spheroid compartments as shown by 
the absence of localization with any of the cell types. Blue DAPI


































































































































Fig. 3  IgG-IL2v therapy-mediated effects. a–c Stimulation of 
immune cell infiltration after 24 h incubation of the heterotypic 
LoVo/MRC-5 spheroids with 100 nM untargeted IgG-IL2v. a Immu-
nohistochemical (CD45, CD3) staining on 3-µm thick serial sections 
of the spheroids. The infiltration rates were calculated based on the 
number of CD45+ leukocytes (b) and CD3+ T cells (c) normalized 
to the spheroid area (two-tailed unpaired t test *p < 0.05, **p < 0.01, 
***p < 0.001, ****p ≤ 0.0001, N = 3–10). d–f Tumor cell elimina-
tion in the heterotypic LoVo/MRC-5 spheroids after 24 h treatment 
with 100 nM untargeted IgG-IL2v assessed by CEA-staining 3-µm 
thick serial sections (d), spheroid size reduction (e) and flow cytom-
etry CEA staining of dissociated spheroids (f) (two-tailed unpaired t 
test *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001, N = 3–10)
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Upon dissociation of spheroids, flow cytometric analy-
sis of the activation status of infiltrated immune cells 
showed an increase in the activation marker CD69 on T 
cells (CD3+), NK cells (CD3−, CD56+), and NK T cells 
(CD3+, CD56+) when treating with IgG-IL2v (Fig. 4b). 
In summary, IgG-IL2v treatment boosted the activity of dif-
ferent immune cell subsets and led to efficient elimination 
of tumor cells.
Investigating the activity of TCBs in monotherapy 
and in combination with IgG‑IL2v using the 3D 
heterotypic spheroid model
Treatment of heterotypic spheroids co-cultured with 
immune cells added to supernatants with CEA TCB or FAP 
TCB resulted in target-specific cross-linking and retention 













































































































































































































































































Fig. 4  Cytokine release and activation of infiltrated immune cells in 
dissociated spheroids. Cytokine/chemokine secretion (CBA analysis, 
a) and immune cell activation (analysis CD69+ status) of subpopu-
lations of infiltrated immune cells in dissociated spheroids (T-, NK-, 
and NKT cells, b) after 24-h treatment with 100 nM untargeted IgG-
IL2v of heterotypic LoVo/MRC-5 spheroids (two-tailed unpaired t 
test *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001, N = 3)
























































































































































































































































Fig. 5  Immune cell infiltration and tumor cell elimination following 
treatment with CEA TCB and FAP TCB in monotherapy and in com-
bination with IgG-IL2v. a CD3 staining of 3-µm thick serial sections 
of heterotypic LS174T/MRC-5 spheroids shows T cell infiltration and 
cross-linking to the tumor compartment (CEA TCB) and to the fibroblast 
compartment (FAP TCB) upon monotherapy with targeted TCBs (50 
nM) and in combination with untargeted IgG-IL2v (10 nM) after 24, 48, 
and 72-h treatment. b T cell infiltration (CD3+ area) within the tumor 
area and fibroblast spheroid area was quantified at 24 h by normalization 
to the tumor and fibroblast-rich areas, respectively (two-tailed unpaired 
t test *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001, N = 3–4). 
c The CEA staining shows elimination of targeted spheroid areas upon 
monotherapy with targeted TCBs (50 nM) and in combination with 
untargeted IgG-IL2v (10 nM) after 24, 48, and 72 h in heterotypic 
LS174T/MRC-5 spheroids. d Reduction in the tumor and fibroblast areas 
in the heterotypic spheroids after treatment was quantified by CEA+ 
and CEA− staining, respectively (two-tailed unpaired t test *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p ≤ 0.0001, N = 3–4)
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respectively. In particular, T cell cross-linking into the 
tumor area was significantly increased when spheroids 
were treated with CEA TCB as monotherapy (28.5-fold) 
and further increased when added in combination with IgG-
IL2v (39.1-fold), as compared with the respective controls 
(Fig. 5a, b). Furthermore, CEA TCB-mediated cross-link-
ing of T cells to tumor cells led to a selective elimination 
of CEA+ tumor areas 72 h post-treatment (Fig. 5c, d), and 
combination of CEA TCB IgG-IL2v further accelerated the 
elimination of tumor areas, reaching statistical significance 
as early as 24 h post-treatment (Fig. 5c, d).
Similarly, T cell cross-linking to fibroblasts was specifi-
cally increased when spheroids/immune cell co-cultures 
were treated with FAP TCB (numerical increase of 7.5-
fold), with a significantly higher increase in combination 
with IgG-IL2v (140.1-fold), as compared with respec-
tive controls (Fig. 5a, b). The fibroblast area (CEA−) 
was reduced by FAP TCB treatment after 72 h (3.7-fold, 
Fig. 5c, d). As seen with CEA TCB, the combination with 
IgG-IL2v accelerated the killing process, resulting in a 
specific reduction in the fibroblast area that reached sta-
tistical significance at 24 h post-treatment and was further 
pronounced at 72 h (5.2-fold, Fig. 5c, d). These results 
indicate that the combination of IgG-IL2v with CEA TCB 
and FAP TCB enhances T cell infiltration and target-spe-
cific T cell cross-linking and retention into the spheroids 
as compared with TCB therapy alone, resulting in faster 
and more efficient elimination of tumor cells or fibro-
blasts bearing the target. The tumor-targeted TCB did not 
increase T cell cross-linking within the fibroblast compart-
ment, and the fibroblast-targeted TCB did not increase T 
cell cross-linking within the tumor compartment, dem-
onstrating target selectivity of the TCBs (Supplementary 
Figure 5).
The heterotypic spheroid cultures also allow meas-
urement of T cell effector function, by measurement of 
cytokines and chemokines in the culture supernatants. 
Release of the T cell effector molecules IFNγ and Gran-
zyme B was significantly increased upon treatment with 
CEA TCB or FAP TCB as compared to untreated controls 
(Fig. 6), and IFNγ and Granzyme B release was signifi-
cantly higher upon combination of TCBs with IgG-IL2v as 
compared to single agents, reflecting the stronger immune 
cell activation following combination treatment.
Fig. 6  IFNγ and Granzyme B 
secretion following treatment 
with CEA TCB and FAP TCB 
in monotherapy and combina-
tion with IgG-IL2v. Cytokine 
release by heterotypic LS174T/
MRC-5 spheroids cultured with 
PBMCs following treatment 
with CEA TCB or FAP TCB 
(50 nM) monotherapy and com-
bination with untargeted IgG-
IL2v (10 nM) after 24 h (two-
tailed unpaired t test *p < 0.05, 
**p < 0.01, ***p < 0.001, 
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Discussion
The 3D heterotypic spheroid model presented here pro-
vides a novel and versatile platform for testing of tumor- 
and fibroblast-targeted cancer immunotherapy agents.
The effects of a TCB antibody in a 3D homotypic sphe-
roid model were recently reported by Hirschhaeuser et al. 
[36]. However, this homotypic 3D model lacked the simul-
taneous presence of tumor cells and fibroblasts. Therefore, 
despite providing valuable information, this homotypic 
model is suboptimal for the assessment of therapies tar-
geted to either tumor or fibroblasts (stroma) and does not 
allow the analysis of immune cell infiltration and activity 
directed to one of the two compartments. Here, we report 
for the first time a novel 3D heterotypic spheroid model 
composed of tumor cells, fibroblasts, and immune cells. 
This allows for cell–cell and cell–matrix interactions in 
a 3D microenvironment where immune cells can infil-
trate and migrate toward both tumor cells and fibroblasts, 
thereby improving the predictability of in vitro testing of 
immunotherapy agents. This novel 3D heterotypic sphe-
roid model more closely resembles the complexity of 
tumors than either homotypic 3D spheroid models or 2D 
culture systems. Two-dimensional models are useful for 
large screening assays of candidate therapeutics to select 
potential drug candidates as killing of tumor target cells or 
fibroblasts in 2D is very efficient. However, the 3D model 
can offer a more realistic picture of the in vivo activity of a 
potential drug candidate.
The 3D spheroids presented in the current manuscript 
represent a novel heterotypic model; however, limita-
tions include the use of tumor and fibroblast cell lines and 
PBMCs derived from healthy individuals added at high E:T 
ratios. Such 3D models could be further optimized by using 
patient-derived tumors containing TILs with physiologi-
cal E:T ratios. Alternatively, infiltration and activation of 
TILs, rather than healthy PBMCS could be investigated, 
given that TILs are frequently suppressed and show subop-
timal activity as compared to PBMCs derived from healthy 
donors.
Specific targeting and retention to tumor and fibroblast 
spheroid areas was demonstrated using tumor- and fibro-
blast-targeted IgG-IL2v (CEA-IL2v and FAP-IL2v, respec-
tively), along with enhanced leukocyte infiltration, activa-
tion, and subsequent elimination of tumor cells. Treatment 
with tumor- or fibroblast-targeted TCB antibodies (CEA 
TCB and FAP TCB, respectively) led to efficient target-
specific cross-linking and retention of T cells to tumor cells 
or fibroblasts, respectively. This resulted in effective elimi-
nation and reduction in the corresponding spheroid areas. 
The combination of both TCBs with IgG-IL2v was more 
efficacious than either monotherapy alone, as shown by an 
increase of immune cell infiltration and activation, faster 
elimination of target cells, and enhanced IFNγ and Gran-
zyme B secretion.
Taken together, the 3D heterotypic model presented here 
enables a comprehensive in vitro evaluation of immune 
cell infiltration and target cell elimination after therapeutic 
intervention, which would not be possible using 2D sys-
tems. The study also demonstrates that tumor- and fibro-
blast-targeted IgG-IL2v and TCBs are promising candi-
dates for combination treatments in cancer immunotherapy.
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